Allakos News


Allakos Expands License Agreement with The Johns Hopkins University School of Medicine


Press Release

SAN CARLOS, Calif. (November 29, 2016 08:30 AM Eastern Standard Time): Allakos, Inc. today announced the expansion of a license agreement with The Johns Hopkins University relating to the intellectual property of Siglec-8, a potential therapeutic target for a variety of diseases related to inflammation and fibrosis, and antibodies to Siglec-8. Under the expanded agreement, Allakos has exclusive rights to The Johns Hopkins University School of Medicine patents and intellectual property covering antibodies to Siglec-8 for therapeutic or diagnostic use.

"Siglec-8 is an inhibitory receptor present exclusively on mast cells, eosinophils and basophils," said Bruce Bochner, MD, the Samuel M. Feinberg Professor of Medicine at Northwestern University. "Antibodies to this receptor have potential for use in the diagnosis and treatment of a number of inflammatory and allergic diseases in which Siglec-8 expressing cells play a role in the biology of the disease." Dr. Bochner is a co-inventor of the licensed technology and co-founder of Allakos, and is also formerly Professor of Medicine and Chief of the Division of Allergy and Clinical Immunology at The Johns Hopkins University School of Medicine.

"Allakos has made rapid progress in developing therapeutic antibodies targeting Siglec-8," commented Dr. Robert Schleimer, the Roy and Elaine Patterson Professor and Chief of Allergy and Immunology at the Northwestern University Feinberg School of Medicine and formerly Professor of Medicine at The Johns Hopkins University School of Medicine. "The company has demonstrated activity of these antibodies in a number of preclinical models, and is currently conducting clinical studies with these antibodies in indications where mast cells or eosinophils are known to play a role in the disease." Professor Schleimer is also a co-inventor of the licensed technology and co-founder of Allakos.

Christopher Bebbington, Chief Executive Officer of Allakos, said, "We are delighted to expand our license agreement with The Johns Hopkins University School of Medicine. We continue to strengthen our intellectual property position relating to antibodies to Siglec-8 for therapeutic and diagnostic purposes, including our lead antibody candidates AK001 and AK002, both of which target the Siglec-8 receptor."

About Allakos

Allakos, a privately held clinical stage biotechnology company, is a scientific leader the field of mast cell biology, focused on the central role these immune system cells play in the pathology of severe inflammatory, fibrotic and proliferative diseases. The company is developing therapeutic antibodies that target a key receptor, Siglec-8, on the surface of mast cells and eosinophils and selectively inhibit the cells’ activity or deplete them from tissues. Antibodies against Siglec-8 offer potential for the development of a broad range of proprietary first-in-class treatments for both serious illnesses affecting large patient populations and rare diseases for which no effective treatments exist. The company currently has two drug candidates in clinical development. AK001 is in a Phase 2 trial for patients with moderate to severe nasal polyposis (with or without asthma). AK002 is in Phase 1 trials in healthy volunteers and in patients with systemic mastocytosis. The company also has a third program focused on development of antibodies that target a novel checkpoint inhibitor for immuno-oncology applications. For further information, please visit www.Allakos.com.

###

Allakos Contact
Simon Greenwood
Chief Business Officer
T: 650 597 5002
media@allakos.com

Media Contact
Nicole Litchfield, nicole@bioscribe.com
or
Joan Kureczka, joan@bioscribe.com



Allakos Appoints Steven P. James to Board of Directors


Press Release

SAN CARLOS, CA (November 3, 2016): Allakos today announced the appointment of Steven P. James to the Allakos Board of Directors. Mr. James is also Executive Chairman and Chief Executive Officer of Precision Immune, Inc., and was the President, CEO, and Director of Labrys Biologics, Inc. from December 2012 until it was acquired by Teva Pharmaceuticals in July 2014.

"Steve has a demonstrated track record of value creation in biotechnology, and we are excited to have him join Allakos as an independent director," said Christopher Bebbington, DPhil., Allakos President and CEO. "Steve’s knowledge and experience will serve Allakos well as our company enters its next stage of growth."

"I am honored to join the board of Allakos," commented Mr. James. "Allakos has a first-rate team, top investors, and a promising pipeline of first-in-class antibodies which address serious and underserved diseases."

Steve James has 25 years of life sciences experience and has been involved in the formation and management of numerous biotechnology companies. Prior to joining Labrys, Steve was President, CEO and Director of KAI Pharmaceuticals, Inc. from October 2004 until the company was acquired by Amgen in July 2012. His previous positions have included Senior Vice President of Commercial Operations at Exelixis; Chief Business Officer at Sunesis Pharmaceuticals and VP of Business Development at Isis Pharmaceuticals (now Ionis). He began his career in new product planning at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree from Brown University. Steve is Chairman of Antiva Biosciences, and a director of Ocera Therapeutics, Chrono Therapeutics, and Cascadian Therapeutics (formerly, Oncothyrean, Inc).

About Allakos

Allakos, a privately held clinical stage biotechnology company, is a scientific leader the field of mast cell biology, focused on the central role these immune system cells play in the pathology of severe inflammatory, fibrotic and proliferative diseases. The company is developing therapeutic antibodies that target a key receptor, Siglec-8, on the surface of mast cells and eosinophils and selectively inhibit the cells’ activity or deplete them from tissues. Antibodies against Siglec-8 offer potential for the development of a broad range of proprietary first-in-class treatments for both serious illnesses affecting large patient populations and rare diseases for which no effective treatments exist. The company currently has two drug candidates in clinical development. AK001 is in a Phase 2 trial for patients with moderate to severe nasal polyposis (with or without asthma). AK002 is in Phase 1 trials in healthy volunteers and in patients with systemic mastocytosis. The company also has a third program focused on development of antibodies that target a novel checkpoint inhibitor for immuno-oncology applications. For further information, please visit www.Allakos.com.

###

Allakos Contact
Simon Greenwood
Chief Business Officer
T: 650 597 5002
media@allakos.com

Media Contact
Nicole Litchfield, nicole@bioscribe.com
or
Joan Kureczka, joan@bioscribe.com



Allakos Antibodies Shown to Inhibit Fibrosis, a Common Cause of Organ Failure


Press Release

Preclinical Data from Multiple Models of Fibrosis and Collagen Deposition Presented at 1st International Conference on Tissue Repair, Regeneration, and Fibrosis

SAN CARLOS, Calif., September 26, 2016 – New preclinical research presented by Allakos, Inc., shows the potential of the company’s recombinant antibodies to Siglec-8, an inhibitory receptor selectively expressed on the immune system’s mast cells and eosinophils, to inhibit fibrosis. The data, presented today at the 1st International Conference on Tissue Repair, Regeneration and Fibrosis in Rhodes, Greece, demonstrate the ability of an anti-Siglec-8 antibody to inhibit multiple elements of the fibrotic process in rodent models of skin and lung fibrosis.

Fibrosis is the formation of fibrous connective tissue in the body and is often part of the repair process in response to injury. However, excessive fibrosis can occur as the main pathology in many diseases — such as idiopathic pulmonary fibrosis, systemic sclerosis, and liver and kidney fibrosis — where it interferes with normal organ function and can lead to organ failure and increased mortality. Mast cells and eosinophils are important cells in the development and progression of fibrosis, where they mediate many processes that result in tissue damage.

Allakos has developed a portfolio of antibodies that bind Siglec-8, a receptor present on mast cells and eosinophils. Previous research has shown that Siglec-8 antibodies can inhibit mast cell function and trigger apoptosis of tissue eosinophils. Allakos has also developed novel Siglec-8 antibodies that can kill mast cells and eosinophils by a natural defense mechanism within the body called antibody-dependent cell-mediated cytotoxicity. The company is currently completing a Phase 1 safety study of an anti-Siglec-8 antibody, AK002, in healthy volunteers, with plans to initiate testing in patients with fibrotic disease in the second half of 2017.

"Our preclinical results demonstrate that a Siglec-8 antibody can reduce key fibrotic processes in multiple animal models," said Nenad Tomasevic, Ph.D., Vice President of Research at Allakos. "The action of these Siglec-8 targeting antibodies is highly specific to mast cells and eosinophils, and has the potential to benefit a wide spectrum of patients with severe, often life-threatening, conditions where fibrosis is a major contributor to the disease."

About Allakos

Allakos is a privately held, clinical-stage company developing a pipeline of novel therapeutics that selectively target mast cells and eosinophils – important immune effector cells that are involved in a broad spectrum of allergic and inflammatory conditions as well as several rare proliferative diseases with high unmet need. The company's lead drug candidates, AK001 and AK002 use novel approaches to target mast cells and eosinophils. AK001 is in a Phase 2 trial in patients with moderate to severe nasal polyposis with or without asthma, and AK002 is currently in two Phase 1 trials – 1) in healthy volunteers and 2) in patients with systemic mastocytosis. Allakos is located in San Carlos, California.

For further information, visit www.Allakos.com.

###

Allakos Contact
Simon Greenwood
Chief Business Officer
T: 650 597 5002
media@allakos.com

Media Contact
Nicole Litchfield, nicole@bioscribe.com
or
Joan Kureczka, joan@bioscribe.com


Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis


Press Release

Rare Proliferative Disease Marked by Excessive Accumulation of Mast Cells in Bone Marrow and Other Organs

SAN CARLOS, Calif., September 15, 2016 – Allakos, Inc. today announced it has initiated dosing of AK002 in a Phase 1 clinical trial in patients with systemic mastocytosis, a rare proliferative disease marked by abnormal accumulation of mast cells, which are key immune system cells involved in allergic and inflammatory responses. The open-label, single ascending-dose study, being conducted in Germany, will evaluate the safety, tolerability and pharmacokinetics of AK002 and will also offer the opportunity to assess markers of activity. AK002 is a therapeutic antibody intended for the treatment of severe diseases characterized by excess activity of mast cells and eosinophils.

"We are very excited that AK002 has entered clinical development, and are looking forward to joining doctors, patients and researchers attending this weekend’s Mastocytosis Society annual conference in Orlando to exchange information about this potentially life-threatening orphan disease,” said Chris Bebbington Ph.D., Chief Executive Officer of Allakos. “This is the second of our portfolio of antibodies to enter clinical trials. AK002 is specifically designed to reduce the number of mast cells, the immune cell type that is increased in patients with systemic mastocytosis. Currently, there are limited treatment options for patients with systemic mastocytosis, and Allakos is focused on rapidly developing novel therapies for patients that suffer from this difficult to manage disease."

Frank Siebenhaar, M.D., of the Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, who, along with Professor Marcus Maurer, M.D., is a principal investigator for this study, commented: "Systemic mastocytosis is a serious disease for which there are no effective treatment options and current therapies primarily focus on managing symptoms. We are excited to collaborate with Allakos in the clinical evaluation of AK002 in patients with systemic mastocytosis."

Allakos is also conducting a Phase I healthy volunteer study with AK002 to further test the safety, pharmacokinetics and pharmacodynamics of this antibody. The study is anticipated to enroll up to 48 subjects. More information is available at https://clinicaltrials.gov/ct2/show/NCT02859701.

Allakos’ first antibody drug candidate, AK001, is currently under investigation in a Phase 2 study of patients with moderate to severe nasal polyposis with or without asthma. More information is available at https://clinicaltrials.gov/ct2/show/NCT02734849.

For further information on the AK002 systemic mastocytosis clinical trial, please visit https://clinicaltrials.gov/ct2/show/NCT02808793.

About Systemic Mastocytosis

Systemic mastocytosis is a disease characterized by excess proliferation of abnormal mast cells. Patients with the indolent form of systemic mastocytosis suffer from multiple mast cell-related symptoms such as severe itching, flushing, hives, abdominal pain and diarrhea and spontaneous anaphylaxis. The current treatments for these patients are focused on managing symptoms; there are no approved therapies that specifically target the underlying cause of the disease. In more aggressive forms of the disease, mast cells affect body organs and limit life expectancy.

About AK002

AK002 is a therapeutic antibody that selectively depletes mast cells and eosinophils. Binding of AK002 to specific receptors present on mast cells and eosinophils results in removal of these cells by a natural defense mechanism within the body called antibody-dependent cell-mediated cytotoxity (ADCC). AK002’s action is highly specific to mast cells and eosinophils and has potential to be of benefit in a wide spectrum of severe, often life-threatening, conditions. AK002 has demonstrated safety and efficacy activity in multiple pre-clinical models of disease prior to beginning clinical studies.

About Allakos

Allakos is a privately held, clinical-stage company developing a pipeline of novel therapeutics that selectively target mast cells and eosinophils – important immune effector cells that are involved in a broad spectrum of allergic and inflammatory conditions as well as several rare proliferative diseases with high unmet need. The company's lead drug candidates, AK001 and AK002 use novel approaches to target mast cells and eosinophils. AK001 is in a Phase 2 trial in patients with moderate to severe nasal polyposis with or without asthma, and AK002 is currently in two Phase 1 trials – 1) in healthy volunteers and 2) in patients with systemic mastocytosis. Allakos is located in San Carlos, California.

For further information, visit www.Allakos.com.

###

Allakos Contact
Simon Greenwood
Chief Business Officer
T: 650 597 5002
media@allakos.com

Media Contact
Nicole Litchfield, nicole@bioscribe.com
or
Joan Kureczka, joan@bioscribe.com


Allakos Initiates Phase 2 Trial of AK001 in Patients with Nasal Polyposis


Press Release

SAN CARLOS, Calif., Sept. 8, 2016 – Allakos, Inc., today announced it has initiated a Phase 2 clinical trial of AK001, its lead therapeutic antibody, in patients with nasal polyposis with and without asthma. This multicenter trial with sites in the U.S. and Europe will evaluate the activity of two dose levels of AK001 compared with placebo. Study results are anticipated in the second half of 2017. AK001 is a therapeutic antibody currently in development for the treatment of severe inflammatory and allergic diseases characterized by excess activity of mast cells and eosinophils.

"Advancing AK001 into a Phase 2 clinical trial in patients is an important milestone for Allakos as we continue clinical development of our therapeutic antibody pipeline," said Chris Bebbington Ph.D., Chief Executive Officer of Allakos. "The rapid and efficient initiation of this international trial is a great reflection on the abilities of the Allakos development team. The novel mechanism by which AK001 works is ideally suited for the treatment of nasal polyps, which are highly enriched for eosinophils and mast cells. Currently, there are limited therapeutic options for patients with nasal polyposis and, if successful, AK001 may offer a safe and effective non-surgical approach to the disease."

The multicenter, randomized, double blind, placebo-controlled study will enroll 70 patients with moderate to severe nasal polyposis with and without asthma at sites in both the U.S. and Europe. For more information, please visit www.clinicaltrials.gov (NCT02734849).

About Nasal Polyposis

Nasal polyposis is a disease characterized by the growth of polyps in the nasal cavities. In the majority of patients, these polyps are highly enriched for mast cells and eosinophils. Patients with nasal polyposis have blocked nasal passages and sinuses with obstructed breathing and impaired sense of taste and smell that can result in a significant impact on quality of life. These patients are also prone to recurrent nasal infections and asthma, which can be severe in nature. Nasal polyposis is difficult to control with current treatment options, which include topical steroids and surgery.

About AK001

AK001 is a therapeutic antibody that selectively targets mast cells and eosinophils. Binding of AK001 to specific receptors present on mast cells and eosinophils results in the inhibition of mast-cell inflammatory signaling and the removal of tissue-based eosinophils. The direct effect of AK001 on mast cells and eosinophils bypasses the redundancy of cytokine signaling pathways without directly affecting other cells of the immune system. AK001 has the potential to be of benefit in a wide spectrum of severe inflammatory and allergic diseases. Allakos has demonstrated activity of AK001 in multiple pre-clinical models and completed a Phase I clinical trial with AK001 in healthy volunteers in which it was well tolerated and demonstrated pharmacodynamic activity.

About Allakos

Allakos is a privately held clinical-stage company developing a pipeline of novel therapeutics that selectively target mast cells and eosinophils; important immune effector cells that are involved in a broad spectrum of inflammatory and allergic conditions as well as several rare proliferative diseases with high unmet need. The company's lead drug candidates AK001 and AK002 use novel approaches to target mast cells and eosinophils and are in clinical development for the treatment of severe inflammatory diseases and other diseases characterized by excess activity of mast cells and eosinophils. Allakos is located in San Carlos, California.

For further information, visit www.Allakos.com.

###

Allakos Contact
Simon Greenwood
Chief Business Officer
T: 650 597 5002
media@allakos.com

Media Contact
Matt Middleman, M.D.
Russo Partners
T: 212-845-4272
matt.middleman@russopartnersllc.com


Allakos Successfully Completes Dosing in Phase 1 Clinical Trial of AK001 and Announces Expansion of its Executive Team


Press Release

SAN CARLOS, Calif., Jan. 19, 2016 -- Allakos, Inc., today announced it has successfully completed dosing in the Phase 1 clinical trial of AK001 in healthy volunteers and subjects with atopic disease. AK001 is a therapeutic antibody intended for the treatment of severe allergic diseases and diseases characterized by excess activity of mast cells and eosinophils. The randomized, double-blind, placebo-controlled, single-ascending-dose study enrolled 34 subjects to evaluate the safety, tolerability and pharmacokinetics of AK001 in a range of potentially active doses and to obtain early signals of pharmacodynamic activity.

Allakos has also strengthened its management team with the appointment of three experienced executives.

Simon Greenwood, Ph.D., Allakos's chief business officer, has over 20 years of experience in the healthcare industry. Prior to joining Allakos, he was investment director for the Roche Venture Fund, where he led investments in Allakos, 23andMe, Biodesy, CytomX, DVS, Epic Sciences, Horizon Discovery, Maculogix, ProActa and Stratos. Prior to the Roche Venture Fund, Simon was the head of GenenFund, Genentech's corporate venture fund, and he also held roles in research and business development at Genentech. Simon holds a Ph.D. in Genetics and Development from Columbia University College of Physicians and Surgeons, where he was a Fulbright Scholar.

Sally Bolmer, Ph.D., vice president of regulatory affairs and development for Allakos, has more than 25 years of experience in the biopharmaceutical industry. Prior to Allakos Sally was senior vice president of development and regulatory affairs at Human Genome Sciences, Inc. Before Human Genome Sciences, she was executive director for regulatory affairs at Centocor, Inc. In her career, Sally has secured approval for five first-in-class biologics, initiated INDs for over 50 indications, and submitted six BLAs for products including murine, chimeric and human antibodies, antibody fragments and fusion proteins. Sally received a bachelor of science in biochemistry from Brown University and a Ph.D. in biological chemistry from the Hershey Medical Center of Penn State University. She had a post-doctorate appointment in applied biological sciences at MIT and was an assistant research professor at Mount Sinai Medical Center in New York City.

Omer Siddiqui, vice president of clinical operations, has more than 15 years of leadership experience in clinical operations and drug development. He has successfully led clinical operations teams in planning and advancing drug candidates from pre-clinical through IND and proof of concept, up to Phase 3 life cycle investment stage. Prior to Joining Allakos, Omer was responsible for the Immunology, Infectious Disease, Neuroscience and Ophthalmology early development clinical operations group at Genentech. Prior to joining Genentech, he was a senior director in the CNS group at INC Research, a contract research organization specializing in planning and executing drug development programs. Omer received his undergraduate degree in biology from the University of Western Ontario in Canada.

Quotes

Christopher Bebbington, D.Phil., chief executive officer and co-founder of Allakos, said, "AK001 is the first of Allakos's antibodies to enter the clinic. As such, the completion of dosing in our Phase 1 clinical trial is an important milestone for Allakos. The addition of Simon, Sally and Omer brings additional leadership and experience to Allakos and we are pleased to have been able to attract these experienced executives to the management team."

Alejandro Dorenbaum, M.D., chief medical officer of Allakos, said, "AK001 is a first-in-class antibody that works by a novel mechanism of action on mast cells and eosinophils. We look forward to continuing the clinical development of AK001 in patients with severe allergic and inflammatory diseases such as recurrent nasal polyposis and chronic obstructive pulmonary disease (COPD)."

About AK001

AK001 is a therapeutic antibody that targets a receptor present on eosinophils and mast cells. Binding of antibody to this receptor causes inhibition of mast cell activity and selective depletion of activated eosinophils. AK001's action is highly specific to mast cells and eosinophils and has potential to be of benefit in a wide spectrum of conditions where these cells are involved. AK001 has demonstrated activity in proprietary pre-clinical models of severe allergic diseases.

About Allakos

Allakos is a clinical-stage company developing antibodies that selectively target mast cells and eosinophils, important effector cells in a broad spectrum of allergic and inflammatory conditions and several rare proliferative diseases. The company's lead antibodies are AK001 and AK002 intended for the treatment of severe allergic diseases and other diseases characterized by excess activity of mast cells and eosinophils. The company has raised a total of $47 million to-date in Series A financing from Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.


Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases


Press Release

San Carlos, CA – September 30, 2014 – Allakos Inc. announced today that it has secured an additional $10 million investment from current investors to fund development of an additional therapeutic antibody.

The additional financing was completed following achievement of a key, pre-specified milestone related to the company’s lead antibody program, and represents an extension of the company’s Series A preferred stock financing, which closed in December 2012. With this additional financing, Allakos has raised a total of $42 million in the Series A round. All of the company’s current investors participated in this additional financing, including Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. “We are pleased to report that we have demonstrated that our lead antibody shows activity in preclinical models and directly affects multiple key cell types involved in inflammation,” said Nenad Tomasevic, Allakos Co-founder and Vice President, Research. “We appreciate the continued confidence placed in our company by our Series A investors,” said Christopher Bebbington, Allakos Co-founder and Chief Executive Officer. “Following the successful achievement of a key preclinical milestone with our lead program, we are excited to advance another promising antibody into formal preclinical development. These two antibodies form a robust platform that can support clinical development in multiple diseases. Our therapeutic antibodies are designed to work through novel mechanisms of action, to have significant safety and efficacy advantages and to have potential in multiple, high-value markets, including large established indications as well as orphan diseases. The additional funding will enable us to advance two programs towards meaningful near-term milestones.” Peter Moldt, PhD., Partner at Novo Ventures and Chairman of the Allakos board of directors, said: “We believe that Allakos’ innovative approach to developing antibody-based therapeutics represents a large and important therapeutic and commercial opportunity. We are delighted with the continued progress of the company and expansion of its development portfolio.”


Chief Medical Officer Appointed

Allakos also announced the appointment of Alejandro Dorenbaum, MD, as Chief Medical Officer. “We are delighted to welcome Alejandro to the Allakos team to lead our clinical development program and advance our growing pipeline of differentiated antibody therapeutics,” said Dr. Bebbington.

“His broad clinical development expertise will be a valuable asset to our company.” Dr. Dorenbaum received his training in medicine at The National Autonomous University in Mexico City, and his pediatric and allergy immunology training at the University of Texas Health Science Center and at Baylor College of Medicine, respectively. Dr. Dorenbaum joined the faculty of the University of California in San Francisco where he was responsible for a program devoted to clinical research and the care of women and children with HIV infection. Dr. Dorenbaum subsequently worked at Chiron Corporation where he held positions in several areas of drug development, including biologics, small molecules and vaccines. At BioMarin Pharmaceutical, Inc., he was responsible for the clinical development of Kuvan®, and at Genentech, he was responsible for the respiratory programs in asthma and cystic fibrosis. Dr. Dorenbaum also served as Chief Medical Officer at Lumena Pharmaceutical until its acquisition by Shire. He maintains an active academic position as Associate Clinical Professor of Pediatrics at Stanford University School of Medicine where he treats patients with allergy and immunological issues.


Allakos Inc. Completes Series A Financing of $32 Million to Develop Antibody Therapeutics for Allergic and Inflammatory Diseases


Press Release

San Mateo, CA – December 17, 2012 –Allakos Inc. announced today that it has completed a $32 million Series A preferred stock financing led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.

Peter Moldt, PhD., Partner at Novo Ventures, Robert Alexander, PhD., Director at Alta Partners and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the Board of Directors. Commented Dr. Moldt: “We believe that Allakos’ innovative approach to developing antibody-based therapeutics represents a large and important therapeutic and commercial opportunity, founded upon a strong scientific rationale and supported by a respected management team with deep experience in therapeutic antibody development. We are pleased to join with these other distinguished investors in supporting their progress.” “We very much appreciate the confidence placed in our company by our Series A investors,” said Christopher Bebbington, DPhil, Founder and Chief Executive Officer of Allakos. “Our therapeutic antibodies are designed to work through novel mechanisms of action, to have significant safety and efficacy advantages and to have potential in multiple, high-value markets, including large therapeutic areas as well as orphan indications. With these proceeds, we are now well positioned to advance our lead program towards meaningful near-term milestones.”